Managed Healthcare Executive December 9, 2024
Researchers are investigating the therapy as a treatment for B-cell malignancies, but they might also investigate as a treatment for multiple sclerosis and lupus.
Swiss pharmaceutical company Roche has announced plans to acquire clinical-stage biopharmaceutical company Poseida Therapeutics based in San Diego, California The two companies have been in partnership since 2022, focusing on developing allogeneic chimeric antigen receptor T-cell (CART-T) therapies that target blood cancers.
With CAR-T therapy, T cells are obtained from the patient’s (autologous) or a donor’s (allogeneic) blood and re-engineered in a laboratory to produce surface proteins that recognize and attach to antigens on the surface of target cells. The process involves growing millions of altered T cells, which are then infused back into the patient....
Today's Sponsors
Today's Sponsor